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Abstract The optimal second- and third-line chemother-
apy and targeted therapy for patients with advanced
esophagogastric cancer is still a matter of debate.
Therefore, a literature search was carried out in
Medline, EMBASE, CENTRAL, and oncology confer-
ences until January 2016 for randomized controlled trials
that compared second- or third-line therapy. We included
28 studies with 4810 patients. Second-line, single-agent
taxane/irinotecan showed increased survival compared to
best supportive care (BSC) (hazard ratio 0.65, 95 % con-
fidence interval 0.53–0.79). Median survival gain ranged
from 1.4 to 2.7 months among individual studies.
Taxane- and irinotecan-based regimens showed equal
survival benefi t . Doublet chemotherapy taxane/
irinotecan plus platinum and fluoropyrimidine was not
different in survival, but showed increased toxicity vs.
taxane/irinotecan monotherapy. Compared to BSC,
second-line ramucirumab and second- or third-line evero-
limus and regorafenib showed limited median survival
gain ranging from 1.1 to 1.4 months, and progression-
free survival gain, ranging from 0.3 to 1.6 months.
Third- or later-line apatinib showed increased survival
benefit over BSC (HR 0.50, 0.32–0.79). Median survival
gain ranged from 1.8 to 2.3 months. Compared to
taxane-alone, survival was superior for second-line
ramucirumab plus taxane (HR 0.81, 0.68–0.96), and
olaparib plus taxane (HR 0.56, 0.35–0.87), with median
survival gains of 2.2 and 4.8 months respectively.
Targeted agents, either in monotherapy or combined with
chemotherapy showed increased toxicity compared to
BSC and chemotherapy-alone. This review indicates that,
given the survival benefit in a phase III study setting,
ramucirumab plus taxane is the preferred second-line
treatment. Taxane or irinotecan monotherapy are alterna-
tives, although the absolute survival benefit was limited.
In third-line setting, apatinib monotherapy is preferred.
Keywords Advanced esophagogastric cancer .
Chemotherapy . Targeted therapy . Second-line . Third-line .
Meta-analysis
1 Introduction
Worldwide, advanced esophageal and gastric cancers are
major causes of mortality [1]. In the first-line setting,
fluoropyrimidine and platinum combinations are preferred
[2]. As virtually all patients become resistant to first-line
treatment, effective second- or later-line treatments are
warranted. Previously, it has been shown that single-
agent irinotecan and taxane as second-line chemotherapy
increase survival compared to best supportive care (BSC)
[3, 4]. Also, targeted agents that were shown to be active
in clinical trials have been introduced into clinical prac-
tice, for example ramucirumab, a vascular endothelial
growth factor receptor-2 (VEGFR-2) inhibitor [5, 6].
Although evidence for active treatments after progression
on first-line (chemo)therapy has been established, to date,
there are several questions that remain unanswered.
First, as Bsalvage^ chemotherapy usually consists of
irinotecan or taxane, these two strategies are generally
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regarded as equally effective [7]. However, a literature
review to assess the possible differences in efficacy, de-
fined as the maximum effect achievable for a drug in
clinical trial setting, and safety of irinotecan and taxane
is not available. Second, to increase the efficacy of
second-line irinotecan or taxane single-agent chemothera-
py, several trials have been conducted in which another
c y t o t o x i c a g e n t , f o r e x am p l e p l a t i n um o r
fluoropyrimidine, was added to a backbone of irinotecan
or taxane. However, the results of these randomized con-
trolled trials (RCT) are inconsistent and despite the pub-
lication of a recent systematic review [8], doublet chemo-
therapy compared to single chemotherapy including the
newes t RCTs ha s no t b e en i nve s t i g a t ed i n a
fluoropyrimidine add-on and platinum add-on subgroup
structured meta-analysis yet. Third, safety data were not
included in recent reviews or meta-analyses, which makes
it more difficult to put the findings into a clinical perspec-
tive [3, 4, 9]. Fourth, many small trials have been con-
ducted with targeted agents that did not receive much
attention in literature reviews or meta-analyses [10, 11]
since usually only larger phase III trials have been includ-
ed [5, 6, 12]. Overview of the smaller trials will help to
identify the potentially most efficacious targeted agents
for future studies. Fifth, in addition to second-line thera-
py, also third- or later-line therapy has been subject of
investigation lately, but an overview is currently missing
[13, 14]. Finally, usually only relative effect sizes are used
in meta-analysis, which may be difficult to interpret in
clinical practice. In order to enhance the clinical applica-
bility of the findings, also a more absolute efficacy sum-
mary statistic should be incorporated into literature re-
views or meta-analyses, for example the absolute median
survival gain from an experimental treatment over the
control treatment/best supportive care.
In sum, the evidence regarding all possible second- or
third-line treatments is inadequately summarized, which
may be difficult for decision-making in clinical practice.
Therefore, we conducted a systematic review and meta-




Medline, EMBASE and the Cochrane Central Register of
Controlled Trials (CENTRAL) were searched for eligible
RCTs up to January 2016. The search strategy consisted of
medical subject headings (MeSH) combined with text words
for esophageal and gastric cancer and with text words associ-
ated with second- or later-line therapy (Table 1). Also, the
conference abstracts of the American Society of Clinical
Oncology (ASCO) and European Society for Medical
Oncology (ESMO) between 1990 and January 2016 were
searched. NHM and EtV screened the titles, abstracts, and full
texts independently. Disagreements were discussed with a
third arbiter (HvL) until consensus was reached.
Table 1 Full search strategy
Medline via Pubmed
(Bstomach neoplasms^ [MeSH terms] or Besophageal neoplasms^
[MeSH terms])
and
(((refractory [title/abstract] or previously treated [title/abstract]) or




1. esophagus tumor/or exp esophagus cancer
2. stomach tumor/or exp stomach cancer
3. ((esophag* or oesophag* or stomach or gastric or gastroesophag* or
gastrooesophag*)adj5 (neoplas* or cancer* or carcino* or






8. 1 or 2 or 3
9. 4 or 5 or 6 or 7
10. exp controlled clinical trial/or randomized.ti,ab. or
randomised.ti,ab. or placebo.ti,ab. or randomly.ti,ab. or trial.ti
11. 8 and 9 and 10
Additional filters:
1. year = B2005–2016^
2. not (conference abstract or conference paper or Bconference review^
or conference proceeding)
3. articles
Central Register of Controlled Trials (CENTRAL)
#1 MeSH descriptor: [esophageal neoplasms] explode all trees
#2 MeSH descriptor: [stomach neoplasms] explode all trees
#3 #1 or #2
#4 (refractory): ti,ab,kw
#5 (previously treated): ti,ab,kw
#6 (salvage treatment): ti,ab,kw
#7 (second line): ti,ab,kw
#8 #4 or #5 or #6 or #7
#9 #3 and #9
Additional filter: trials
Conference search
Searching journal content for gastric (all words) in title or abstract and
random* or advance* OR metasta* (all words) in full text, from
Jan 2004 through Jan 2016 in http://www.ascopubs.org/search and
http://www.annonc.oxfordjournals.org/search
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2.2 Study selection
Studies had to meet the following criteria of eligibility:
(1) prospective phase II or III randomized controlled
trials; (2) included patients with pathologically proven
metastatic, unresectable, or recurrent adenocarcinoma
of the esophagus, gastro-esophageal junction (GEJ), or
stomach; (3) patients were previously treated with sys-
temic therapy.
2.3 Data extraction and quality assessment
The major efficacy outcome of interest was overall sur-
vival (OS), since an international expert consensus panel
stated that OS as endpoint in oncology clinical trials is
most appropriate [15]. Other outcomes of interest were
progression-free survival (PFS) and the incidence of grade
3–4 adverse events (AEs) to assess the safety (http://ctep.
cancer.gov). Two reviewers (LN and RM) were involved
in data extraction; discrepancies were solved by
discussion with an arbiter (EtV). The quality of the
included studies was assessed using the Cochrane Risk
of bias tool (version 5.1.0). Items were scored as low,
high, or unknown risk of bias.
2.4 Statistical analysis
For time-to-event outcomes OS and PFS, hazard ratios
(HR) with 95 % confidence intervals (95 % CI), number
of events or p values were extracted to calculate the
logHR and standard error based on intention-to-treat
study populations [16]. Also, medians were extracted
to calculate the absolute median OS and PFS gain
(Δmedian) in months from an experimental treatment
over the control treatment arm. The Δmedians were
shown for individual studies and the range of
Δmedians for comparisons with multiple studies. For
the comparison of grade 3–4 AEs between groups, the
number of events and sample-sizes were used to calcu-
late risk ratios (RR) and 95 % CI’s. Review Manager
5.3 was used for statistical analysis.
First, we examined the efficacy and safety of second-
line chemotherapy compared to best supportive care
(BSC). Second, we compared the efficacy and safety
of irinotecan- and taxane-based chemotherapy regimens.
Third, the efficacy and safety of combination chemo-
therapy compared to chemotherapy-alone was examined.
Fourth, single targeted agents were compared to a ref-
erence arm of BSC. Fifth, the added value of targeted
therapy to chemotherapy compared to chemotherapy-
alone was examined. Finally, targeted agents for specific
molecular subgroups were examined.
In case of statistical heterogeneity, as tested with the
Cochran Q and quantified by the I2 index, baseline
characteristics in the corresponding studies were ex-
plored and subsequent sensitivity analysis conducted
by omitting the heterogeneous studies. All comparisons
were tested at a significance level of α = 0.05.
3 Results
3.1 Description of the studies
A total of 423 unique references were identified in Medline,
EMBASE, and CENTRAL. Of the remaining 284 reports af-
ter title/abstract screening, 8 studies were excluded based on
full text. Searching conference abstracts provided five addi-
tional studies. In total, 28 studies (N = 4810 patients) were
included (Fig. 1). The number of studies that scored low risk
of bias on all items of the Cochrane risk of bias tool for the
primary outcome was 18 (64 %) (Fig. 2a). Five studies (18 %)
were reported as meeting abstract or presentation. The risk of
bias assessment for PFS is summarized in Fig. 2b. All patients
included in the studies received a plat inum and
fluoropyrimidine-based first-line chemotherapy regimen
(Table 2). No major differences in sex, age, disease status
and Eastern Collaborative Oncology Group (ECOG) perfor-
mance status were observed between the included studies, as
shown in Table 2. In the majority of the studies, the inclusion
was restricted to patients with an ECOG performance status of
0 or 1, as indicated in Table 2. In the following sections,
recommendations about the performance status of patients to
be eligible for a certain therapy are based on performance
status as inclusion criterion of the specific trials (Table 2).
3.2 Single cytotoxic agent compared to best supportive
care
Increased overall survival was found for single cytotoxic
agents vs. BSC (HR 0.65, 0.53–0.79) by meta-analysis of 3
studies including 410 patients as shown in Fig. 3 [17–19]. In
subgroup analysis, increased OS was shown for both taxane
(HR 0.71, 0.56–0.90) and irinotecan (HR 0.55, 0.40–0.77)
compared to BSC. Absolute median survival gain ranged from
Δ1.4 toΔ1.6 months for taxane compared to BSC and ranged
from Δ1.6 to Δ2.7 months for irinotecan compared to BSC
(Table 3). Both taxane and irinotecan were associated with
statistically significant increased grade 3–4 neutropenia (33/
207 vs. 2/198, RR 12.17, 3.41–43.50) and febrile neutropenia
(9/100 vs. 0/91, RR 8.69, 1.14–66.42) compared to BSC.
Taxane or irinotecan as second-line monotherapy can
be used in the second-line setting to treat patients with
a performance status of 0 to 2, but the modest absolute
Cancer Metastasis Rev (2016) 35:439–456 441
survival benefit compared to best supportive care should
be considered.
3.3 Taxane-based compared to irinotecan-based
chemotherapy
Meta-analysis of four studies including 604 patients
showed that there was no difference between taxane-
based and irinotecan-based regimens in OS (HR 0.94,
0.78–1.13) and PFS (HR 0.84, 0.69–1.03), with absolute
median OS gains ranging from Δ−1.3 to Δ1.1 months
and absolu te PFS gains ranging f rom Δ0.1 to
Δ1.3 months (Fig. 4; Table 3)[19–22]. Irinotecan was
associated with increased grade 3–4 neutropenia, diarrhea
and anorexia compared to taxane, whereas taxane was
associated with increased neuropathy (Table 3). In sum,
taxane and irinotecan were similar in efficacy. For an in-
dividual patient, a taxane or irinotecan can be chosen
based on the specific toxicity profile of these agents.
Taxane and irinotecan will be regarded as comparators
in the next sections.
3.4 Combination chemotherapy compared to single-agent
taxane or irinotecan
The effect of adding cisplatin, oxaliplatin or fluoropyrimidine
to single-agent irinotecan or taxane was assessed in three stud-
ies including 341 patients [23–25], in one study including 52
Studies eligible for systematic review
n = 24
References for full-text assessment
n = 32
References derived from Medline (n = 174), EMBASE 
(n = 198) and CENTRAL (n = 51) until January 2016
Total n = 423
Additional studies identified from 
conference meetings
n = 5
Unique references for screening based on title and abstract
n = 284
References derived from ASCO (n = 1265) 
and ESMO (n = 504) until January 2016
Total n = 1769
Studies derived from both database and conference search that were eligible for systematic review: n = 29
- Single agent chemotherapy versus BSC: n = 3
- Taxane- versus irinotecan-based chemotherapy: n = 4 
- Doublet versus single agent chemotherapy: n = 10
- Single targeted agent versus BSC or placebo: n = 5
- Targeted agent versus chemotherapy-alone: n = 1
- Targeted agent combined with chemotherapy versus chemotherapy-alone: n = 7
Excluded based on title and abstract 
n = 1764
Excluded after detailed assessment: n = 8
- No chemotherapy or targeted therapy: n = 1
- Study compared different dosing regimen: n = 1
- Cohort study: n = 2
- Study compared reverse sequence regimens: n = 2
- Not randomized: n = 1
- Study included squamous cell carcinoma: n = 1




Fig. 1 Flowchart of included studies. Flowchart of references derived
from database search (left) and from conference search (right). Notes: the
study of Kang and colleagues (2012) [19] was included in both the single-
agent chemotherapy vs. BSC as well as the taxane- vs. irinotecan-based
chemotherapy comparison
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patients [26] and in six studies including 629 patients [21, 25,
27–30] respectively (Fig. 5; Table 3). A HR for OS and PFS
could not be calculated for one small study [30].
Meta-analysis showed that doublets were not more ef-
fective compared to single agents in OS (HR 1.00, 0.90–
1.12) and no significant differences were found with
a bFig 2 Risk of bias assessment for
overall survival and progression-
free survival. Risk of bias
assessment for the primary
outcome overall survival (a) and
progression-free survival (b). The
green spots with a Bplus sign^
indicate low risk of bias on an
item, whereas the yellow spots
with Bquestion mark^ indicate
unknown risk of bias on an item.
Notes: single-center studies and
studies without a published full
article report were rated unclear
risk of other possible bias. The
absence of a description of a
blinded-imaging review
committee was not regarded of
bias for OS, since the primary
outcome OS would not be
influenced by this parameter
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subgroup analysis by type of additional cytotoxic agent.
On the other hand, the pooled effect for PFS was signif-
icant (HR 0.81, 0.73–0.90). Subgroup analysis showed
that the addition of oxaliplatin to the taxane or irinotecan
backbone was associated with increased PFS with HR
0.64 (0.48–0.85) and absolute median PFS gain of
Δ2.9 months. Also, the addition of fluoropyrimidine re-
sulted in longer PFS with HR 0.84 (0.72-0.97), but abso-
lute median PFS gain ranged from Δ0 to Δ1.4 months
only. The cisplatin-based subgroup did not reach statisti-
cal significance over monotherapy. No statistically signif-
icant heterogeneity was detected in any of the analyses
(Fig. 5; Table 3). Overall, none of the grade 3–4 adverse
events showed statistically significant differences between
doublet and monotherapy, although a general trend to-
wards increased toxicity could be observed for doublets
(Table 4). Exploratory subgroup analysis showed that
oxaliplatin-based doublets were associated with signifi-
cantly increased grade 3–4 neutropenia (8/25 vs. 0/27,
RR 18.31, 1.11–301.60) and fluoropyrimidine-based dou-
blets with increased grade 3–4 anemia (37/292 vs. 26/336,
RR 1.65, 1.02–2.66).
One study including 100 patients was analyzed sepa-
rately, since only patients with peritoneal metastasis were
included and seven out of 48 patients (15 %) in the meth-
otrexate plus 5-FU combination arm did in fact receive 5-
FU monotherapy [31]. Taxane monotherapy was associat-
ed with increased PFS (HR 0.57, 0.37–0.88) compared to
a combination of methotrexate and 5-FU or 5-FU mono-
therapy (Table 3). There was no difference in OS. An
increased rate of grade 3–4 neutropenia was found for
methotrexate plus 5-FU vs. taxane (14/49 vs. 6/51, RR
2.43, 1.02–5.81). In sum, combination chemotherapy is
not recommended as second-line treatment due to lack
of superior efficacy at the cost of additional toxicity.
3.5 Single targeted agents compared to best supportive
care
Meta-analysis was only possible for apatinib compared to pla-
cebo with 2 studies including 408 patients [13, 14], since all
other targeted agents were investigated in one study only. In
Table 5, the efficacy and statistically significant grade 3–4
adverse events of single targeted agents compared to BSC
and single cytotoxic agents are summarized.
In second-line setting, ramucirumab monotherapy showed
increased benefit in both OS, HR 0.78 (0.61–1.00) with abso-
lute median OS gain of Δ1.4 months and in PFS, HR 0.48
(0.38–0.62) with absolute median PFS gain of Δ0.8 months
compared to BSC. In second- or third-line setting, no OS
benefit of the mammalian target of rapamycin (mTOR) inhib-
itor everolimus and the multityrosine kinase inhibitor regoraf-
enib was found over BSC. Increased PFS was found for both
everolimus, HR 0.66 (0.56–0.78), with median PFS gain of
Δ0.3 months and for regorafenib, HR 0.41 (0.28–0.59), with
median PFS gain of Δ1.6 months respectively. As third- or
later-line therapy, apatinib, a tyrosine kinase inhibitor that se-
lectively inhibits VEGFR-2, showed increased OS and PFS,
HR 0.50 (0.32–0.79) and HR 0.27 (0.14–0.51) vs. BSC, with a
median OS gain ranging fromΔ1.8 toΔ2.3 months and PFS
gain ranging from Δ0.8 to Δ2.3 months.
In Table 5, only grade 3–4 AEs were reported for which a
statistically significant difference exist between the occur-
rence in the treatments arms. Compared to BSC, significantly
Fig. 3 Overall survival in studies comparing single-agent taxane and
irinotecan to best supportive care. Forest-plot of single-agent taxane and
irinotecan compared to best supportive care in terms of overall survival
(A). BSC best supportive care, IRI irinotecan, TAX taxane, PTX paclitaxel,
DTX docetaxel
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increased grade 3–4 toxicities were anorexia, hypokalemia,
thrombocytopenia, and stomatitis for second-or third-line
everolimus, and hand-foot syndrome and hypertension with
third- or later-line apatinib (Table 5). None of the AEs associ-
ated with second-line ramucirumab and second- or third-line
regorafenib reached statistical significance compared to BSC.
In sum, in third-line single-agent apatinib and in second-line
single-agent ramucirumabmay be considered for patients with
performance status 0 or 1 who cannot or do not want to un-
dergo chemotherapy. However, the modest absolute survival
benefit compared to best supportive care should be taken into
consideration.
3.6 The addition of a targeted agent to chemotherapy
compared to chemotherapy-alone
In second-line setting, increased OS was shown for
ramucirumab plus taxane (HR 0.81 0.68–0.96), with a
median survival gain of Δ2.2 months, and for the en-
zyme poly-ADP ribose polymerase [PARP] inhibitor
olaparib plus taxane (HR 0.56, 0.35–0.87), with a me-
dian survival gain of Δ4.8 months compared to taxane-
alone. Also, increased PFS was found for ramucirumab
plus taxane (HR 0.64, 0.54–0.75), with a median PFS
gain of Δ1.5 months, but not for olaparib plus taxane
(Table 5). In second- or third-line setting, the epidermal
growth factor receptor [EGFR] inhibitor nimotuzumab
plus irinotecan and the multityrosine kinase inhibitor
sunitinib plus irinotecan-based chemotherapy did not
show any significant difference in OS and PFS com-
pared to chemotherapy-alone (Table 5). Compared to
chemotherapy-alone, second-line ramucirumab plus
taxane was associated with increased grade 3–4 hyper-
tension, fatigue and neuropathy and both second-line
olaparib plus taxane and second-or third-line sunitinib
plus chemotherapy were associated with increased neu-
tropenia (Table 5). None of the AEs associated with
second- or third-line nimotuzumab plus taxane reached
statistical significance compared to taxane-alone.
In sum, based on results of phase III studies ramucirumab
plus taxane is the only combination therapy that can be rec-
ommended as second-line therapy for patients with a perfor-
mance status of 0–1. Olaparib in combination with a taxane
shows potential as a second-line regimen when results are
confirmed by phase III results.
3.7 Targeted agents in specific molecular sub-populations
In HER-2 positive patients, the addition of lapatinib, a
dual inhibitor of EGFR and HER-2 tyrosine kinase activ-
ity, to a taxane as second-line regimen was not associated
with increased efficacy in OS and PFS over taxane-alone










































































































































































































































































































































448 Cancer Metastasis Rev (2016) 35:439–456
the immunohistochemistry (IHC) 3+ subgroup for OS
(HR 0.59, 0.37-0.93) and PFS (HR 0.54 0.33-0.90) [36].
The addition of capecitabine to lapatinib vs. lapatinib
alone showed no difference in both OS and PFS in an
HER-2 positive population [37]. Furthermore, one small
study failed to demonstrate a benefit in OS or PFS for the
fibroblast growth factor receptor (FGFR)1-3 inhibitor
AZD-4547 over taxane-alone in a FGFR-2-amplificated
population [35] (Table 5). In sum, there is no evidence
for HER-2 directed second-line therapy, although
lapatinib plus taxane showed promising efficacy in pa-
tients with HER2 IHC 3+.
3.8 Best supportive care: palliative treatment
for obstruction and dysphagia
Stent placement, intraluminal brachytherapy, or
intraluminal balloon dilatation are widely accepted pallia-
tive procedures to relief obstruction and dysphagia caused
by locally advanced esophageal tumours [38, 39]. On the
one hand, stent placement can provide rapid palliation but
there is a risk of complications, compared to brachyther-
apy. On the other hand, brachytherapy is associated with
long-term relief and with fewer complications compared
to stent placement, but it takes longer before relief of
symptoms is initiated [40]. Also, it has been shown that
the combination of both brachytherapy and stent place-
ment is more effective in survival and symptom relief
compared to stent placement-alone [41]. Guidelines rec-
ommend the concurrent use of these palliative procedures
and multimodality therapy, for example chemotherapy or
targeted therapy, but these procedures should be carefully
chosen based on the patients’ prognosis and needs.
4 Discussion
In this systematic review we showed that both taxane and
irinotecan as single agents significantly prolonged survival
compared to BSC. Although the hazard ratios were statistical-
ly significant, the absolute survival benefit was marginal and
this should be taken into consideration in clinical practice. In
contrast to earlier meta-analyses, the current meta-analysis
provided evidence that taxane and irinotecan-based regimens
are equally effective in terms of both OS and PFS. However,
the two regimens showed a different toxicity profile, which
may guide clinical decision-making in the use of a specific
cytotoxic agent in an individual patient.
No OS benefit was detected for the addition of another
cytotoxic agent (i.e., platinum or fluoropyrimidine) to a back-
bone of taxane or irinotecan. The addition of fluoropyrimidine
significantly resulted in a statistically significant pooled HR of
0.84, but it is debatable whether a 16 % risk reduction of PFS
is clinically relevant. According to a large international expert
consensus panel, OS as endpoint in oncology clinical trials is
more appropriate and a HR ≤ 0.80 is clinically relevant [15].
The panel stated a similar or even stricter criterion for PFS
compared to the criterion of OS. The HR of 0.84 in the current
meta-analysis does not meet the criterion of HR ≤ 0.80 for
PFS. Moreover, the majority of the studies within this com-
parison did not show any absolute gain in median PFS. Of
note, PFS was prolonged by the addition of oxaliplatin (HR
0.64, 0.48–0.85) in a small phase II study with patients that
a
b
Fig. 4 Studies comparing taxane-based and irinotecan-based
chemotherapy. Forest-plot of taxane-based compared to irinotecan-
based chemotherapy terms of overall survival (a) and progression-free
survival (b). Notes: Roy 2012 irinotecan and PEP02 arms were pooled
and compared to the docetaxel arm. BSC best supportive care, IRI
irinotecan, TAX taxane, PTX paclitaxel, DTX docetaxel
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received cisplatin in the first-line treatment [26], so the poten-
tial of oxaliplatin for cisplatin-refractory patients could be
subject of a larger prospective study. Based on this evidence,
and acknowledging that toxicity was increased with
a
b
Fig. 5 Studies comparing doublet and single-agent chemotherapy. The
efficacy of doublet chemotherapy regimen, consisting of a taxane or
irinotecan backbone combined with cisplatin, oxaliplatin, or
fluoropyrimidine, vs. taxane or irinotecan single agent in terms of
overall survival (a) and progression-free survival (b). BSC best
supportive care, IRI irinotecan, TAX taxane, PTX paclitaxel, DTX
docetaxel
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combination therapy, we conclude that there is currently no
role for combination chemotherapy in the second-line setting.
Regarding targeted therapy, the current systematic review
provided evidence from phase III studies for three treatments.
Second-line ramucirumab plus taxane significantly prolonged
OS and PFS compared to taxane-alone with a clinically rele-
vant absolute survival gain in patients with performance status
0 or 1 [6]. On the other hand, second-line ramucirumab as
monotherapy showed a marginal absolute survival gain com-
pared to BSC [5]. Apatinib monotherapy is currently the only
treatment that has been tested in a third- or later-line setting (in
both phase II and III studies) and might be clinically relevant
in terms of relative and absolute gain in survival for patients
with ECOG performance status 0 or 1 [13, 14]. In phase II
studies, regorafenib monotherapy met its primary outcome
criterion PFS by a HR of 0.41, but the median gain in PFS
was only 1.6 months. Future large prospective studies should
indicate if regorafenib could be utilized in second- or third-
line setting [32]. Although olaparib plus taxane did not meet
its primary endpoint PFS, OS was significantly prolonged as
quantified by a HR of 0.56 and an absolute survival gain of
median 4.8 months [34]. Results of a phase III RCT are
awaited for olaparib (NCT01924533). Evidence for the addi-
tion of lapatinib to taxane in an HER-2 positive population
was weak; only patients with HER2 IHC 3+ benefited from
lapatinib while toxicity was increased [36].
We also discuss the limitations of this review. First, some
studies with targeted agents, such as regorafenib monotherapy
[32], were conducted in second- as well as in third-line setting.
This makes the assessment of the specific indication for the
targeted agent difficult. However, the study population is homo-
geneous as all included patients were refractory to
fluoropyrimidine and platinum-based regimens. Furthermore, ex-
cept for apatinib and sunitinib, meta-analysis was not possible for
the majority of targeted agents since those were examined in a
single study only. As most targeted agents have different mecha-
nisms of action, pooling would introduce heterogeneity and
would complicate the interpretation of results.Moreover, the over-
view of both relative and absolute efficacy results as well as the
statistically significant grade 3–4 adverse events provided in
Table 5 might be sufficient to value each targeted agent against
current evidence.
In conclusion, based on the currently available phase
III evidence, ramucirumab plus taxane can be regarded
standard treatment for fit patients with a performance
status of 0 or 1, who wish to undergo second-line treat-
ment. The phase III results of olaparib in combination
with paclitaxel are eagerly awaited. Combination chemo-
therapy has currently no role in the second-line treatment
due to lack of efficacy. Taxane or irinotecan as mono-
therapy might be alternatives for patients with a perfor-
mance status of 2 and thus not eligible for ramucirumab
plus taxane or for patients with performance status 0 or 1
who prefer monotherapy. However, the modest absolute
survival benefit of taxane or irinotecan monotherapy
compared to best supportive care should be considered.
Apatinib is a valuable option as third-line therapy for fit
patients with a performance status of 0 or 1, again with
limited absolute survival benefit. Finally, patient with a
performance status larger than 2 after first- or second-
line therapy, should be offered BSC.
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